ArticleAAPS PharmSciTech2025
Amorphization of Albendazole Using Organic Acid-based Solid Dispersions for Improved Dissolution: A Solvent-free Approach.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tailored Drug Release with Improved Solubility via Spray Drying and Functional Ready-to-Fill Capsules.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albendazole (ABZ), a broad-spectrum anthelmintic drug, exhibits poor aqueous solubility and low oral bioavailability (< 5%), limiting its therapeutic effectiveness. This study introduces an organic solvent-free strategy to enhance ABZ dissolution by preparing solid dispersions (SDs) with weak organic acids-citric acid (CA), tartaric acid (TA), and glutaric acid (GA). pH-dependent solubility analysis showed that all three acids improved ABZ solubility, with CA achieving the most pronounced effect-a 188,000-fold increase compared to intrinsic solubility of ABZ (0.25 µg/mL). SDs were formulated at varying ABZ-to-acid molar ratios (1:0.5 to 1:3) using concentrated acid solutions, followed by drying. PXRD confirmed complete amorphization of ABZ in CA-based SDs at 1:1 and higher ratios, while TA and GA resulted in partial amorphization. FTIR and solution-phase
Indexed as
Identifiers
40936041What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.